Mar42019 Anavex Life Sciences Reports Publication of New Data that Show ANAVEX®2-73 Induces Cellular Recycling Process Linked to the Prevention and Treatment of Age-Associated Diseases March 4, 2019
Feb72019 Anavex Life Sciences Reports Fiscal 2019 First Quarter Financial Results And Provides Clinical Study Updates February 7, 2019
Jan312019 Anavex Life Sciences to Announce Fiscal 2019 First Quarter Financial Results on Thursday, February 7th, 2019 January 31, 2019
Jan22019 Anavex Life Sciences Announces the Appointment of Walter E Kaufmann, MD as Chief Medical Officer January 2, 2019
Dec122018 Anavex Life Sciences Reports Fiscal Year 2018 Financial Results And Provides Clinical Study Update December 12, 2018
Dec102018 Anavex Life Sciences to Announce 2018 Fiscal Year End Financial Results on Wednesday, December 12, 2018 December 10, 2018
Nov82018 Anavex Life Sciences Strengthens its Scientific Advisory Board with Distinguished Researcher for Clinical Treatment of Parkinson’s Disease Dementia (PDD) November 8, 2018
Oct302018 First Patient Enrolled in Anavex Life Sciences Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Parkinson’s Disease Dementia (PDD) October 30, 2018
Oct262018 Anavex Life Sciences Presents New Three-Year, Longitudinal Clinical Efficacy Data for ANAVEX®2-73 in Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting October 26, 2018
Oct192018 Anavex Life Sciences Announces FDA Approval of IND for Phase 2 Trial of ANAVEX®2-73 in Patients with Rett Syndrome October 19, 2018
Sep262018 Anavex Life Sciences to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference September 26, 2018
